Assessing the potential of pharmaceuticals and their transformation products to cause mutagenic effects: Implications for gene expression profiling

Keyphrases

• Gene Expression Profiling 100%
• Transformation Products 100%
• Mutagenic Effects 100%
• Mutagenicity 75%
• Estrogenicity 50%
• Gene Expression Profile 25%
• Challenging Tasks 25%
• Mitogen-activated Protein Kinase 25%
• Estrogenic 25%
• Human Health 25%
• Propranolol 25%
• Carbamazepine 25%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 25%
• Beta-blockers 25%
• Aspartate Metabolism 25%
• Mixture Composition 25%
• Phototransformation Products 25%
• Alanine Metabolism 25%
• P53 Gene 25%
• Mixture Effects 25%
• Glutamate Metabolism 25%
• Metoprolol 25%
• T47D-KBluc 25%
• Atenolol 25%
• Sulfamethoxazole 25%
• Organizational Level 25%
• Synergistic Effect 25%
• Mass Spectrometry Analysis 25%
• Environment Health 25%
• Trimethoprim 25%
• Mutagenic Compounds 25%
• Ultra Performance 25%
• Transformation Pathways 25%
• Ofloxacin 25%
• Spliceosome 25%
• Azithromycin 25%
• Diclofenac 25%
• Gene Expression Microarray 25%
• Photolabile 25%
• Kinase Assay 25%
• Erythromycin 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug 100%
• Mutagenicity 60%
• Glutamic Acid 20%
• Mitogen Activated Protein Kinase 20%
• Propranolol 20%
• Carbamazepine 20%
• Ibuprofen 20%
• Protein P53 20%
• Atenolol 20%
• Phosphotransferase 20%
• Aspartic Acid 20%
• Ofloxacin 20%
• Alanine 20%
• Azithromycin 20%
• Metoprolol 20%
• Cotrimoxazole 20%
• Diclofenac 20%
• Erythromycin 20%